Table 8.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Kidney-Pancreas Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	748	919	860	853	972	943	914	891	905	870
Tx With Immunosuppression Info	748	918	860	851	970	937	906	887	898	845
No Induction Drugs Recorded	51.6%	34.4%	18.6%	25.6%	34.7%	33.9%	26.7%	24.4%	23.5%	21.1%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	1.5%	7.1%	32.2%	36.8%	13.4%	6.2%	3.0%	2.6%	2.8%	1.9%
OKT3	47.5%	60.5%	52.3%	42.8%	27.7%	15.5%	8.2%	3.6%	1.2%	0.2%
Thymoglobulin	0.0%	0.0%	0.2%	0.1%	0.4%	8.6%	23.0%	28.7%	39.1%	48.6%
Zenapax	0.1%	0.3%	0.1%	0.4%	20.5%	27.0%	21.9%	20.0%	16.4%	8.4%
Simulect	0.1%	0.3%	0.1%	0.4%	8.5%	17.1%	27.2%	31.1%	26.4%	16.2%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	7.3%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.